MX2021000068A - Formas y composiciones farmaceuticas de ivosidenib. - Google Patents

Formas y composiciones farmaceuticas de ivosidenib.

Info

Publication number
MX2021000068A
MX2021000068A MX2021000068A MX2021000068A MX2021000068A MX 2021000068 A MX2021000068 A MX 2021000068A MX 2021000068 A MX2021000068 A MX 2021000068A MX 2021000068 A MX2021000068 A MX 2021000068A MX 2021000068 A MX2021000068 A MX 2021000068A
Authority
MX
Mexico
Prior art keywords
ivosidenib
forms
pharmaceutical compositions
formulations
further provided
Prior art date
Application number
MX2021000068A
Other languages
English (en)
Inventor
Shijie Zhang
Chong - Hui Gu
Jacob Paul Sizemore
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2021000068A publication Critical patent/MX2021000068A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan formulaciones de ivosidenib que incluyen varios polimorfos. Se proporcionan además formulaciones de ivosidenib que contienen varias impurezas conocidas. Se proporcionan además composiciones adicionales estables de ivosidenib.
MX2021000068A 2018-07-06 2019-07-02 Formas y composiciones farmaceuticas de ivosidenib. MX2021000068A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862694596P 2018-07-06 2018-07-06
PCT/US2019/040257 WO2020010058A1 (en) 2018-07-06 2019-07-02 Ivosidenib forms and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX2021000068A true MX2021000068A (es) 2021-03-25

Family

ID=69059942

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021000068A MX2021000068A (es) 2018-07-06 2019-07-02 Formas y composiciones farmaceuticas de ivosidenib.
MX2023011687A MX2023011687A (es) 2018-07-06 2021-01-06 Formas y composiciones farmaceuticas de ivosidenib.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023011687A MX2023011687A (es) 2018-07-06 2021-01-06 Formas y composiciones farmaceuticas de ivosidenib.

Country Status (17)

Country Link
US (1) US20210323944A1 (es)
EP (1) EP3817744A4 (es)
JP (1) JP2021529805A (es)
KR (1) KR20210029775A (es)
CN (1) CN112367995A (es)
AU (1) AU2019299352A1 (es)
BR (1) BR112021000156A2 (es)
CA (1) CA3103498A1 (es)
EA (1) EA202190217A1 (es)
IL (1) IL279877A (es)
MA (1) MA53099A (es)
MX (2) MX2021000068A (es)
PH (1) PH12021550017A1 (es)
SG (1) SG11202012763TA (es)
TW (1) TW202019419A (es)
WO (1) WO2020010058A1 (es)
ZA (1) ZA202008034B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4010331T (lt) * 2019-08-08 2023-11-10 Les Laboratoires Servier Ivosidenibo ir jo tarpinio junginio gavimo būdas
GB201912411D0 (en) * 2019-08-29 2019-10-16 Johnson Matthey Plc Crystalline forms of ivosidenib

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108524505A (zh) 2009-03-13 2018-09-14 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
ES2594402T3 (es) 2009-10-21 2016-12-20 Agios Pharmaceuticals, Inc. Métodos y composiciones para trastornos relacionados con la proliferación celular
WO2012137111A1 (en) * 2011-04-08 2012-10-11 Pfizer Inc. Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
JO3479B1 (ar) * 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب
MA39725B1 (fr) * 2014-03-14 2021-09-30 Les Laboratoires Servier Sas Compositions pharmaceutiques de composés thérapeutiquement actifs
KR20240010105A (ko) * 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
MX2018004586A (es) * 2015-10-15 2018-08-16 Agios Pharmaceuticals Inc Terapia de combinacion para tratar tumores malignos.
WO2017146795A1 (en) * 2016-02-26 2017-08-31 Agios Pharmaceuticals, Inc. Idh1 inhibitors for the treatment of haematological malignancies and solid tumours
WO2019104318A1 (en) * 2017-11-27 2019-05-31 Teva Pharmaceuticals Usa, Inc. Solid state forms of ivosidenib

Also Published As

Publication number Publication date
TW202019419A (zh) 2020-06-01
ZA202008034B (en) 2021-10-27
IL279877A (en) 2021-03-01
JP2021529805A (ja) 2021-11-04
EA202190217A1 (ru) 2021-04-16
MX2023011687A (es) 2023-10-19
EP3817744A1 (en) 2021-05-12
AU2019299352A1 (en) 2021-01-07
EP3817744A4 (en) 2022-07-13
SG11202012763TA (en) 2021-02-25
MA53099A (fr) 2021-05-12
CN112367995A (zh) 2021-02-12
BR112021000156A2 (pt) 2021-04-06
KR20210029775A (ko) 2021-03-16
PH12021550017A1 (en) 2021-09-13
US20210323944A1 (en) 2021-10-21
CA3103498A1 (en) 2020-01-09
WO2020010058A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
PH12020552154A1 (en) Compounds
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
MX2021002529A (es) Analogos de illudin, usos de los mismos y metodos para sintetizar los mismos.
MX2023011687A (es) Formas y composiciones farmaceuticas de ivosidenib.
IL283286A (en) Pharmaceutical formulations of cyclosporine analogs
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
JOP20200155A1 (ar) صور متعددة الأشكال
IL283593A (en) Bernaflam oral preparations
EP4175626A4 (en) NEW PHARMACEUTICAL COMPOSITIONS
MX2018005376A (es) Derivados de azetidina para formacion de imágenes de tau.
IN2014MU00859A (es)
MX2018010652A (es) Composiciones farmaceuticas.
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
MX2017010992A (es) Composiciones farmaceuticas estables que comprenden agente antibacteriano.
GB202005742D0 (en) Novel pharmaceutical compositions
ZA202104675B (en) Anticancer compounds
IL310652A (en) Radiprodil formulations
MX2021002923A (es) (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometoxi)bencil) piperazin-1-carboxilato cristalino, composiciones y sus metodos de uso.
GB202108259D0 (en) Novel formulations
EP3773516A4 (en) Pharmaceutical composition of nintedanib esylate
GB202004814D0 (en) Novel formulations
GB202004811D0 (en) Novel Formulations